
|Articles|January 18, 2002
What's New on the CBER Web Site 12/24/2001 through 12/28/2001
Author(s)BioPharm International Editors
Recall of reagent red blood cells (two notices) and advisory committee meetings
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
2
GSK Acquisition of RAPT Signals Shift Toward Long-Acting Anti-IgE Therapies
3
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
4
How Biopharma Navigates the 2026 Economic Shift
5




